ReviewOrphanet journal of rare diseases2015
Progressive hemifacial atrophy: a review.
Review in Orphanet journal of rare diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- Epilepsy in Parry-Romberg syndrome and linear scleroderma en coup de sabre: Case series and systematic review including 140 patients.Epilepsy & behavior : E&B · 2021Pooled it
- Parry-Romberg Syndrome: Radioclinical Dissociation in a Paucisymptomatic Form and a Proposed Diagnostic Framework.Diagnostics (Basel, Switzerland) · 2026Article
- Long-term follow-up of linear scleroderma en coup de sabre in children with central nervous system involvement.Frontiers in immunology · 2026Article
- Leptin From Fibro-Adipogenic Progenitor Cells (FAPs) Regulates Masseter Muscle Disuse Atrophy and Ectopic Fat Accumulation.Journal of cachexia, sarcopenia and muscle · 2025Article
- Article
- Parry-Romberg Syndrome with Localized Plaque Morphea and Localized Discoid Lupus Erythematosus: A Case Report of a Rare Overlap.Indian dermatology online journal · 2025Article
- Ocular manifestations and treatment progress of Parry-Romberg syndrome.International ophthalmology · 2025Review
- Treatment of Mild-to-moderate Progressive Hemifacial Atrophy by Acellular Dermal Matrix Combined With Preoperative Digital Evaluation.Plastic and reconstructive surgery. Global open · 2025Article
- Parry Romberg syndrome: A case report.Radiology case reports · 2024Article
- Outcomes of Fat Grafting in the Active Versus Quiescent Phase of Localized Scleroderma.Plastic surgery (Oakville, Ont.) · 2024Article
- Article
- Article
- A case report of Parry-Romberg syndrome.Clinical case reports · 2024Article
- Immunological Profiles in Parry-Romberg Syndrome: A Case-Control Study.Journal of clinical medicine · 2024Article
- Hemimasticatory spasm: a series of 17 cases and a comprehensive review of the literature.Frontiers in neurology · 2024Article
- Disturbances of the stomatognathic system and possibilities of its correction in patients with craniofacial morphea.Postepy dermatologii i alergologii · 2023Review
- Clinical and therapeutic course in head variants of linear morphea in adults: a retrospective review.Archives of dermatological research · 2023Article
- Article
- A Case of Linear Scleroderma in a Young Child: A Diagnosis Easily Missed in Primary Care.The American journal of case reports · 2023Article
- Morphea: The 2023 update.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgressive Hemifacial Atrophy (PHA) is an acquired, typically unilateral, facial distortion with unknown etiology. The true incidence of this disorder has not been reported, but it is often regarded as a subtype of localized scleroderma. Historically, a debate existed whether PHA is a form of linear scleroderma, called morphea en coup de sabre (ECDS), or whether these conditions are inherently different processes or appear on a spectrum (; Adv Exp Med Biol 455:101-4, 1999; J Eur Acad Dermatol Venereol 19:403-4, 2005). Currently, it is generally accepted that both diseases exist on a spectrum of localized scleroderma and often coexist. The pathogenesis of PHA has not been delineated, but trauma, autoimmunity, infection, and autonomic dysregulation have all been suggested. The majority of patients have initial manifestations in the first two decades of life; however, late presentations in 6th and 7th decades are also described [J Am Acad Dermatol 56:257-63, 2007; J Postgrad Med 51:135-6, 2005; Neurology 61:674-6, 2003]. The typical course of PHA is slow progression over 2-20 years and eventually reaching quiescence. Systemic associations of PHA are protean, but neurological manifestations of seizures and headaches are common [J Am Acad Dermatol 56:257-63, 2007; Neurology 48:1013-8, 1997; Semin Arthritis Rheum 43:335-47, 2013]. As in many rare diseases, standard guidelines for imaging, treatment, and follow-up are not defined.
methodsThis review is based on a literature search using PubMed including original articles, reviews, cases and clinical guidelines. The search terms were "idiopathic hemifacial atrophy", "Parry-Romberg syndrome", "Romberg's syndrome", "progressive hemifacial atrophy", "progressive facial hemiatrophy", "juvenile localized scleroderma", "linear scleroderma", and "morphea en coup de sabre". The goal of this review is to summarize clinical findings, theories of pathogenesis, diagnosis, clinical course, and proposed treatments of progressive hemifacial atrophy using a detailed review of literature. INCLUSION- AND EXCLUSION CRITERIA: Review articles were used to identify primary papers of interest while retrospective cohort studies, case series, case reports, and treatment analyses in the English language literature or available translations of international literature were included.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.